UBS Downgrades Forest Labs (FRX) to Neutral
More News related to FRX
- Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
- Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression
- Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
- Goldman Sachs Initiates Coverage on Several Pharmaceutical Companies - CEPH, ENDP, FRX, KG, SEPR & WCRX
- Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
More News related to Downgrades
- ARGUS Downgrades Smith International (SII) to Hold
- Cantor Fitzgerald Downgrades Audiocodes (AUDC) to Hold After Negative 4Q Preannouncement
- MDB Capital Downgrades Ener1 (HEV) to Sell, Suspends Earnings Model and Valuation on Stock No Longer Justified
- DA Davidson Downgrades Ambassadors Group (EPAX) to Neutral
- SunTrust Downgrades Ruby Tuesday, Inc. (RT) to Neutral
UBS downgrades Forest Laboratories (NYSE: FRX) from Buy to Neutral.
Forest Laboratories, Inc., together with its subsidiaries, develops, manufactures, and sells branded and generic forms of ethical drug products, and non-prescription pharmaceutical products.
Related Categories
DowngradesStocks Mentioned
+0.08Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
